Skip to main content
SpringerLink
Log in

Agomelatine and Depressions

  • Living reference work entry
  • First Online:
NeuroPsychopharmacotherapy

  • 57 Accesses

Abstract

Agomelatine is an antidepressant drug acting as melatonergic MT1- and MT2-receptor agonist and selective serotonergic 5-HT2C-antagonist. The efficacy in treatment of major depressive disorder was established in randomized, double-blind, placebo controlled studies and a maintenance study in adult in- and outpatients. Positive effects on sleep parameters have been reported. Side effects are rare; weight gain, sexual dysfunction, or discontinuation syndromes are missing; increase of hepatic transaminases values must be monitored, however; and agomelatine is contraindicated in patients with liver impairment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Cipriani A, Furukawa TA, Salanti G, Chaimani A, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391:1357–66.

    Article  CAS  Google Scholar 

  • Corruble E, de Bodinat C, Belaidi C, Goodwin G. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int J Neuropsychopharmacol. 2013;16:2219–34.

    Article  CAS  Google Scholar 

  • De Berardis D, Conti CM, Marini S, Ferri F, et al. Is there a role for agomelatine in the treatment of anxiety disorders? A review of published data. Int J Immunopath Pharmacol. 2013;26:299–304.

    Article  Google Scholar 

  • Demyttenaere K, Corruble E, Hale A, Quera-Salva MA, Picarel-Blanchot F, Kapser S. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. CNS Spectr. 2013;18:163–70.

    Article  Google Scholar 

  • Dridi D, Zouiten A, Mansour HB. Depression: chronophysiology and chronotherapy. Biol Rhythm Res. 2013;45:77–91.

    Article  Google Scholar 

  • Friedrich ME, Akimova E, Huf W, Konstantinidis A, et al. Drug-induced liver injury during antidepressant treatment: results of AMSP, a drug surveillance program. Int J Neuropsychopharmacol. 2016;19:pyv126.

    Article  Google Scholar 

  • Goodwin G, Emsley R, Rembry S, Rouillon F, et al. Agomelatine prevents relapse in patients with major depressive disorder, without evidence of a discontinuation syndrome. J Clin Psychiatry. 2009;70:1128–37.

    Article  Google Scholar 

  • Gorwood P, Benichou J, Moore N, Martínez EA, et al. The safety of agomelatine in standard medical practice in depressed patients: a 26-week international multicentre cohort study. Hum Psychopharmacol. 2021;36:e2759.

    Article  Google Scholar 

  • Guaiana G, Gupta S, Chiodo D, Davies SJ, Haederle K, Koesters M. Agomelatine versus other antidepressive agents for major depression. Cochrane Database Syst Rev. 2013;12:CD008851.

    Google Scholar 

  • Hale A, Corral R, Mencacci O, Saiz Ruiz J, Albarran SC. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomised, double-blind study. Int Clin Psychopharmacol. 2010;25:305–14.

    Article  Google Scholar 

  • Heun R, Ahokas A, Boyer P, et al. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder. A placebo-controlled study. J Clin Psychiatry. 2013;74:587–94.

    Article  CAS  Google Scholar 

  • Hiemke C, Bergemann N, Clement HW, Conca A, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9–62.

    Article  CAS  Google Scholar 

  • Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf. 2011;34:709–31.

    Article  CAS  Google Scholar 

  • Kasper S, Hamon M. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. World J Biol Psychiatry. 2009;10:117–26.

    Article  Google Scholar 

  • Kasper S, Hajak G, Wulff K, Hoogendijk WJ, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry. 2010;71:109–20.

    Article  CAS  Google Scholar 

  • Kasper S, Corruble E, Hale A, Lemoine P, et al. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control. Int Clin Psychopharmacol. 2013;28:12–9.

    Article  Google Scholar 

  • Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder. CNS Drugs. 2010;24:479–99.

    Article  CAS  Google Scholar 

  • Koesters M, Guaiana G, Cipriani A, Becker T, Barbui C. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. Br J Psychiatry. 2013;203:179–87.

    Article  Google Scholar 

  • Laux G. The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI. Pharmacopsychiatry. 2012;45:284–29.

    Article  CAS  Google Scholar 

  • Laux G, Barthel B, Hajak G, et al. Pooled analysis of four non-interventional studies: Effectiveness and tolerability of the antidepressant agomelatine in daily practice. Adv Ther. 2017;34:895–914.

    Article  CAS  Google Scholar 

  • Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry. 2007;68:1723–32.

    Article  CAS  Google Scholar 

  • Martinotti G, Sepede G, Gambi F, Di Iorio G, et al. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study. J Clin Psychopharmacol. 2012;32:487–91.

    Article  CAS  Google Scholar 

  • Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306:954–64.

    Article  CAS  Google Scholar 

  • Montgomery SA, Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol. 2007;22:283–91.

    Article  Google Scholar 

  • Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol. 2004;19:271–80.

    Article  CAS  Google Scholar 

  • Norman TR, Olver JS. Agomelatine for depression: expanding the horizons? Expert Opin Pharmacother. 2019;20:647–56.

    Article  CAS  Google Scholar 

  • Nussbaumer-Streit B, Greenblatt A, Kaminski-Hartenthaler A, et al. Melatonin and agomelatine for preventing seasonal affective disorder. Cochrane Database Syst Rev. 2019;6:CD011271.

    PubMed  Google Scholar 

  • Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol. 2007;10:661–73.

    CAS  PubMed  Google Scholar 

  • Papakostas GI, Nielsen RZ, Dragheim M, Tonnoir B. Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response. J Psychiatr Res. 2018;101:72–9.

    Article  Google Scholar 

  • Pjrek E, Winkler D, Konstantinidis A, Willeit M, et al. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology (Berl). 2007;190:575–9.

    Article  CAS  Google Scholar 

  • Pladevall-Vila M, PottegÃ¥rd A, Schink T, Reutfors J, et al. Risk of acute liver injury in agomelatine and other antidepressant users in four European countries: a cohort and nested case–control study using automated health data sources. CNS Drugs. 2019;33:383–95.

    Article  CAS  Google Scholar 

  • Quera Salva MA, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol. 2007;10:691–6.

    CAS  PubMed  Google Scholar 

  • Quera-Salva MA, Hajak G, Philip P, Montplaisir J, et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol. 2011;26:252–62.

    Article  Google Scholar 

  • Racagni G, Riva MA, Molteni R, Musazzi L, et al. Mode of action of agomelatine: synergy between melatonergic and 5-HT(2C) receptors. World J Biol Psychiatry. 2011;12:574–87.

    Article  Google Scholar 

  • Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol. 2012;15:417–28.

    Article  CAS  Google Scholar 

  • Stein DJ, Ahokas A, Marquez MS, Höschl C, et al. Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study. J Clin Psychiatry. 2014;75:362–8.

    Article  CAS  Google Scholar 

  • Taylor D, Sparshatt A, Varma S, et al. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ. 2014;348:g1888.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Psychological Medicine (IPM), Soyen, Germany

    Gerd Laux

Authors
  1. Gerd Laux
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerd Laux .

Editor information

Editors and Affiliations

  1. Dept Psychiatry , Psychosomatics & Psychotherapy, University of Würzburg, Medical School Clinical Neurochemistry, Würzburg, Germany

    Peter Riederer

  2. Inst für Psychologische Medizin, Haag, Bayern, Germany

    Gerd Laux

  3. Fujita Health University School Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Würzburg, Bayern, Germany

    Christian Riederer

Section Editor information

  1. Institute of Psychological Medicine (IPM), Soyen, Germany

    Gerd Laux MD PhD ipl.-Psych.

  2. Department of Psychiatry, Ludwig-Maximilians-University Munich, Munich, Germany

    Hans-Jürgen Möller

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Laux, G. (2021). Agomelatine and Depressions. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_31-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56015-1_31-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56015-1

  • Online ISBN: 978-3-319-56015-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation